andrea casadei gardini
Università Vita-Salute San Raffaele
H-index: 38
Europe-Italy
Top articles of andrea casadei gardini
MiR-22 regulates HIF-1A pathway and tumor progression and represents a possible biomarker of sorafenib response in hepatocellular carcinoma
Digestive and Liver Disease
2024/2/1
Controversies in upper GI oncology: first-line systemic treatment in MASLD-associated HCC
ESMO open
2024/2/1
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with …
BMC cancer
2024/4/8
Rossana Berardi
H-Index: 37
Andrea Casadei Gardini
H-Index: 24
Davide Melisi
H-Index: 27
Salvatore Siena
H-Index: 66
Giovanni Brandi
H-Index: 35
Same-session endoscopic diagnosis and symptom palliation in pancreato-biliary malignancies: Clinical impact of rapid on-site evaluation (ROSE)
Endoscopy International Open
2024/2
Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian …
Digestive and Liver Disease
2024/2/1
Pathogenic alterations in PIK3CA and KMT2C are frequent and independent prognostic factors in anal squamous cell carcinoma treated with salvage …
International Journal of Cancer
2024/2/1
ASO Visual Abstract: Minimally Invasive Approach Provides Oncological Benefit in Patients with High Risk of Very Early Recurrence (VER) After Surgery for Intrahepatic …
Annals of surgical oncology
2024/1/31
Andrea Casadei Gardini
H-Index: 24
Francesco De Cobelli
H-Index: 37
Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab
Liver International
2024/3/22
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma
Targeted Oncology
2024/1/22
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab
2024/3/21
Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma …
2024/1/20
Minimally invasive approach provides oncological benefit in patients with high risk of very early recurrence (VER) after surgery for intrahepatic cholangiocarcinoma (iCCA)
Annals of Surgical Oncology
2024/1/2
Andrea Casadei Gardini
H-Index: 24
Francesco De Cobelli
H-Index: 37
Defining and predicting textbook outcomes for perihilar cholangiocarcinoma: analysis of factors improving achievement of desired postoperative outcomes
HPB
2023/1/1
α‐FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
International Journal of Cancer
2024/3/15
Regional Differences in Clinical Presentation and Prognosis of Patients With Post–Sustained Virologic Response Hepatocellular Carcinoma
Clinical Gastroenterology and Hepatology
2024/1/1
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study
Targeted Oncology
2024/5/1
Characteristics and outcome of anti‐hepatitis D virus positive patients with hepatocellular carcinoma
Liver International
2024/3/1
Andrea Pasta
H-Index: 3
Filippo Pelizzaro
H-Index: 1
Maria Guarino
H-Index: 22
Gerardo Nardone
H-Index: 35
Gianpaolo Vidili
H-Index: 15
Franco Trevisani
H-Index: 42
Alessandro Granito
H-Index: 34
Francesco Tovoli
H-Index: 23
Fabio Farinati
H-Index: 40
Calogero Cammà
H-Index: 50
Paolo Giuffrida
H-Index: 1
Andrea Casadei Gardini
H-Index: 24
Fabio Conti
H-Index: 6
Giorgio Ercolani
H-Index: 43
Mario Capasso
H-Index: 26
Filomena Morisco
H-Index: 31
Federico Ravaioli
H-Index: 14
Luca Marzi
H-Index: 5
More than shots in the dark: improving patient stratification to move closer to personalised therapies in intrahepatic cholangiocarcinoma
Gut
2024/3/1
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab
Targeted Oncology
2024/2/12
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab
Liver International
2021/12
Co-Authors
